Patents by Inventor Jamie G. Bates

Jamie G. Bates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
    Publication number: 20240091351
    Abstract: Provided are methods of treating, mitigating, reducing, preventing or delaying the growth, proliferation, recurrence or metastasis of a solid cancer in a mammalian subject in need thereof comprising co-administering to the subject an effective amount of radiation therapy (RT) focally-delivered to the solid cancer; and an agent that inhibits binding between CD47 and SIRP?.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 21, 2024
    Inventors: Hikmat H. Assi, Jamie G. Bates
  • COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS
    Publication number: 20230355796
    Abstract: Provided are methods of treating, mitigating, or preventing or delaying the growth, proliferation, recurrence or metastasis of, a Trop-2 expressing cancer in a subject by administering an effective amount of: (a) an agent that inhibits binding between CD47 and SIRP? (e.g., magrolimab); and (b) an anti-Trop-2 antibody drug conjugate (ADC) (e.g., sacituzumab govitecan) to the subject.
    Type: Application
    Filed: March 21, 2023
    Publication date: November 9, 2023
    Inventors: Mark P. Chao, William J. Grossman, Inderjit D. Lal, Fatema A. Legrand, Nathalie Scholler, Jamie G. Bates, Hikmat H. Assi, Chih-Chien Chou
  • Thienopyrimidine derivatives as ACC inhibitors and uses thereof
    Patent number: 11352371
    Abstract: The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: June 7, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie G. Bates, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Brian J. Kirby, Yurong Lai, Michael L. Mitchell, Gregg M. Schwarzwalder, James G. Taylor, Ting Wang
  • THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF
    Publication number: 20210053990
    Abstract: The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: August 6, 2020
    Publication date: February 25, 2021
    Inventors: Jamie G. Bates, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Brian J. Kirby, Yurong Lai, Michael L. Mitchell, Gregg M. Schwarzwalder, James G. Taylor, Ting Wang